915 Stock Overview
Shandong Wit Dyne Health Co.,Ltd. engages in the pharmaceutical business in China.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 6/6 |
Rewards
Risk Analysis
No risks detected for 915 from our risk checks.
Shandong Wit Dyne Health Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥34.31 |
| 52 Week High | CN¥39.33 |
| 52 Week Low | CN¥24.06 |
| Beta | 0.16 |
| 1 Month Change | -1.24% |
| 3 Month Change | 23.20% |
| 1 Year Change | -2.20% |
| 3 Year Change | 17.10% |
| 5 Year Change | 50.61% |
| Change since IPO | 313.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| 915 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -3.7% | -1.1% | -0.4% |
| 1Y | -2.2% | -15.9% | -16.2% |
Return vs Industry: 000915 exceeded the CN Pharmaceuticals industry which returned -15.9% over the past year.
Return vs Market: 000915 exceeded the CN Market which returned -16.2% over the past year.
Price Volatility
| 915 volatility | |
|---|---|
| 915 Average Weekly Movement | 4.8% |
| Pharmaceuticals Industry Average Movement | 7.9% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.4% |
Stable Share Price: 000915 has not had significant price volatility in the past 3 months.
Volatility Over Time: 000915's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 1,763 | Jie Yang | www.sd-wit.com |
Shandong Wit Dyne Health Co.,Ltd. engages in the pharmaceutical business in China. Its medical products include azithromycin granules, licorice zinc granules, compound calcium carbonate, vitamin AD drops, epalrestat tablets, valsartan hydrochlorothiazide gums, roxithromycin, rosiglitazone tartrate tablets, and glimepiride tablets.
Shandong Wit Dyne Health Co.,Ltd. Fundamentals Summary
| 915 fundamental statistics | |
|---|---|
| Market cap | CN¥8.27b |
| Earnings (TTM) | CN¥590.17m |
| Revenue (TTM) | CN¥2.49b |
13.6x
P/E Ratio3.2x
P/S RatioIs 915 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 915 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.49b |
| Cost of Revenue | CN¥346.13m |
| Gross Profit | CN¥2.15b |
| Other Expenses | CN¥1.56b |
| Earnings | CN¥590.17m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.52 |
| Gross Margin | 86.12% |
| Net Profit Margin | 23.66% |
| Debt/Equity Ratio | 0% |
How did 915 perform over the long term?
See historical performance and comparison